<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02902913</url>
  </required_header>
  <id_info>
    <org_study_id>617247</org_study_id>
    <nct_id>NCT02902913</nct_id>
  </id_info>
  <brief_title>Impact of Extra Virgin Olive Oil Oleocanthal Content on Platelet Reactivity</brief_title>
  <official_title>Impact of Extra Virgin Olive Oil Oleocanthal Content on Platelet Reactivity in Healthy Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>USDA, Western Human Nutrition Research Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data from limited dietary intervention trials suggest that the cardiovascular health benefit&#xD;
      of extra virgin olive oil (EVOO) may increase with phenolic content. However, while EVOOs&#xD;
      contain an array of bioactive compounds, little information exists regarding the&#xD;
      physiological effects of specific chemical species. Among the EVOO-derived phenolics with&#xD;
      demonstrated anti-inflammatory effects in animal and in vitro models is oleocanthal, an&#xD;
      inhibitor of cyclooxygenase (COX). The current study compared the impact of acute intake (40&#xD;
      mL) of EVOO on platelet reactivity in healthy adult males (n=9). The volunteers were randomly&#xD;
      assigned to consume three EVOOs in a double-blind controlled trial. The EVOO were&#xD;
      characterized and chosen for equivalency in their total phenolic content and fatty acid&#xD;
      profiles, but differing in their oleocanthal to oleacein ratio.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ten healthy adult males (20-50 years of age) will be enrolled into a randomized triple-blind,&#xD;
      controlled crossover study that will test the acute effects of oleocanthal-rich extra virgin&#xD;
      olive oil intake on platelet aggregation. Each participant will be asked to participate in&#xD;
      four study days, separated by at least 1-week, in which they will be randomized to consume on&#xD;
      each study day 40 mL (~3 tablespoons) of either oleocanthal-rich extra virgin olive oil (OO),&#xD;
      or an extra virgin OO that is matched in total phenolics but oleocanthal-poor, or a refined&#xD;
      OO that is low in all phenolics In addition to the oils, on a fourth study day visit, after&#xD;
      completion of the study visits involving oil intake the subjects will be asked to take 400mg&#xD;
      of ibuprofen.&#xD;
&#xD;
      Collection procedures will be performed at the same time of the day to avoid circadian&#xD;
      effects. A blood sample (50 mL ~ 3.5 tbsp) will be collected for the measurement of platelet&#xD;
      aggregometry and COX metabolites. Following this initial blood draw, the subjects will&#xD;
      consume their assigned test product for the day. Two-hours following the intake of the&#xD;
      assigned olive oil, a second blood sample will be drawn (50 mL ~ 3.5 tbsp). After the second&#xD;
      blood draw, the study day will be complete.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>All participants received all four interventions in a randomized, cross-over design in which both participant and caregiver were masked to the assignment (with the exception of the fourth intervention, ibuprofen, which was always administered at the final study visit).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Optical Platelet Aggregometry</measure>
    <time_frame>Change from baseline 2 hours post intake</time_frame>
    <description>Maximal platelet aggregation in minutes will be measured using optical platelet aggregometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activated Platelet Oxylipin Production</measure>
    <time_frame>Change from baseline 2 hours post intake</time_frame>
    <description>Oxylipins derived from cyclooxygenase, lipoxygenase, and cytochrome P450 dependent metabolism of AA were quantified using liquid chromatography with tandem mass spectrometry (LC-MS/MS) in 100 µL of PRP plasma activated with collagen or ADP as well as 100 µL of unactivated PRP plasma collected before and two hours after treatment with EVOO or ibuprofen.&#xD;
Data were mean centered and reported as a % change from baseline.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Oleocanthal-rich, D2i2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oleocanthal-rich, D2i2 (Extra virgin olive oil containing oleocanthal to oleacein in a 2:1 ratio)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oleacein-rich, D2i0.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oleacein-rich, D2i0.5 (Extra virgin olive oil containing oleocanthal to oleacein in a 1:2 ratio)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oleocanthal and Oleacein-low, D2i0</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oleocanthal and Oleacein-low, D2i0 (Extra virgin olive oil containing low amounts of oleocanthal to oleacein, but with a similar total phenolic content as the other two oils)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen, 400 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>D2i2</intervention_name>
    <description>Oleocanthal provided in a 2:1 ratio compared to oleacein</description>
    <arm_group_label>Oleocanthal-rich, D2i2</arm_group_label>
    <other_name>Oleocanthal-rich</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>D2i0.5</intervention_name>
    <description>Oleocanthal provided in a 1:2 ratio compared to oleacein</description>
    <arm_group_label>Oleacein-rich, D2i0.5</arm_group_label>
    <other_name>Oleocanthal-low</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>D2i0</intervention_name>
    <description>No oleocanthal and no oleacein</description>
    <arm_group_label>Oleocanthal and Oleacein-low, D2i0</arm_group_label>
    <other_name>Control EVOO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>400 mg of Ibuprofen</description>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to comply with study protocols&#xD;
&#xD;
          -  Willing to drink 2 tablespoons of olive oil&#xD;
&#xD;
          -  BMI 18.5 to 30 kg/m2&#xD;
&#xD;
          -  Weight ≥ 110 pounds&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults who are not able to consent&#xD;
&#xD;
          -  BMI ≥ 31 kg/m2&#xD;
&#xD;
          -  Under current medical supervision&#xD;
&#xD;
          -  Self-reported daily use of drugs that are known to affect platelet function, such as&#xD;
             aspirin, Excedrin, and NSAIDS&#xD;
&#xD;
          -  Ibuprofen intolerance or allergy&#xD;
&#xD;
          -  Cannot speak English&#xD;
&#xD;
          -  Allergy to olives or olive oil&#xD;
&#xD;
          -  Vegetarian, Vegan, food faddists, individuals using non-traditional diets, on a weight&#xD;
             loss diet or individual following diets with significant deviations from the average&#xD;
             diet of the general population.&#xD;
&#xD;
          -  A history of cardiovascular disease, stroke, cancer, renal, hepatic, or thyroid&#xD;
             disease, GI tract disorders, previous GI surgery&#xD;
&#xD;
          -  Currently taking prescription drugs or supplements&#xD;
&#xD;
          -  Indications of substance or alcohol abuse within the last 3 years&#xD;
&#xD;
          -  Not willing to stop any supplement use, including herbal, plant or botanical, fish&#xD;
             oil, oil supplements.&#xD;
&#xD;
          -  Not willing to refrain from olive oil consumption.&#xD;
&#xD;
          -  Blood Pressure ≥ 140/90 mmHg&#xD;
&#xD;
          -  Self-reported malabsorption&#xD;
&#xD;
          -  Metabolic panel results or complete blood counts that are outside of the normal&#xD;
             reference range.&#xD;
&#xD;
          -  Screening LDL ≥ 190 mg/dl for those who have 0 - 1 major risk factors apart from LDL&#xD;
             cholesterol [(i.e. family history of premature coronary artery disease (male first&#xD;
             degree relative &lt; 55 years; CHD in female first degree relative &lt; 65 years), cigarette&#xD;
             smoker, HDL-C ≤ 40 mg/dL].&#xD;
&#xD;
          -  Screening LDL ≥ 160 mg/dl for those who have 2 major risk factors apart from LDL&#xD;
             cholesterol [(i.e. family history of premature coronary artery disease (male first&#xD;
             degree relative &lt; 55 years; CHD in female first degree relative &lt; 65 years), cigarette&#xD;
             smoker, HDL-C ≤ 40 mg/dL].&#xD;
&#xD;
          -  Screening LDL ≥ than 130 mg/dl for those who have 2 major risk factors apart from LDL&#xD;
             cholesterol ((i.e. family history of premature coronary artery disease (male first&#xD;
             degree relative &lt; 55 years; CHD in female first degree relative &lt; 65 years), cigarette&#xD;
             smoker, HDL-C ≤ 40 mg/dL), and a Framingham 10 - year Risk Score 10 - 20 % (using NCEP&#xD;
             calculator).&#xD;
&#xD;
          -  Current enrollee in a clinical research study.&#xD;
&#xD;
          -  Individuals with blood clotting or platelet defect disorders&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberta R Holt, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/29904393/</url>
    <description>manuscript</description>
  </link>
  <results_reference>
    <citation>Agrawal K, Melliou E, Li X, Pedersen TL, Wang SC, Magiatis P, Newman JW, Holt RR. Oleocanthal-rich extra virgin olive oil demonstrates acute anti-platelet effects in healthy men in a randomized trial. J Funct Foods. 2017 Sep;36:84-93. doi: 10.1016/j.jff.2017.06.046. Epub 2017 Jul 3.</citation>
    <PMID>29904393</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <results_first_submitted>July 26, 2018</results_first_submitted>
  <results_first_submitted_qc>October 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 7, 2019</results_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>platelet reactivity</keyword>
  <keyword>phenolic</keyword>
  <keyword>extra virgin olive oil</keyword>
  <keyword>cyclooxygenase</keyword>
  <keyword>oleocanthal</keyword>
  <keyword>oxylipin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>All participants received all four study interventions. The first three interventions were administered in random order:&#xD;
Oleocanthal-rich, D2i2&#xD;
Oleacein-rich, D2i0.5&#xD;
Oleocanthal and Oleacein-low, D2i0&#xD;
All participants received the last intervention, 400 mg of Ibuprofen, at the fourth (final) study visit.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>First Intervention (1 Day)</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Washout (7 Days)</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Second Intervention (1 Day)</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Washout (7 Days)</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Third Intervention (1 Day)</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Washout (7 Days)</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ibuprofen (400mg)</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All participants received all four study interventions. The first three interventions were administered in random order:&#xD;
Oleocanthal-rich, D2i2&#xD;
Oleacein-rich, D2i0.5&#xD;
Oleocanthal and Oleacein-low, D2i0&#xD;
All participants received the last intervention, 400 mg of Ibuprofen, at the fourth (final) study visit.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Optical Platelet Aggregometry</title>
        <description>Maximal platelet aggregation in minutes will be measured using optical platelet aggregometry</description>
        <time_frame>Change from baseline 2 hours post intake</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants received all four study interventions. The first three interventions were administered in random order:&#xD;
Oleocanthal-rich, D2i2&#xD;
Oleacein-rich, D2i0.5&#xD;
Oleocanthal and Oleacein-low, D2i0&#xD;
All participants received the last intervention, 400 mg of Ibuprofen, at the fourth (final) study visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Optical Platelet Aggregometry</title>
          <description>Maximal platelet aggregation in minutes will be measured using optical platelet aggregometry</description>
          <units>percentage of maximal aggregation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D2i2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D2i0.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D2i0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ibuprofen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.5" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Activated Platelet Oxylipin Production</title>
        <description>Oxylipins derived from cyclooxygenase, lipoxygenase, and cytochrome P450 dependent metabolism of AA were quantified using liquid chromatography with tandem mass spectrometry (LC-MS/MS) in 100 µL of PRP plasma activated with collagen or ADP as well as 100 µL of unactivated PRP plasma collected before and two hours after treatment with EVOO or ibuprofen.&#xD;
Data were mean centered and reported as a % change from baseline.</description>
        <time_frame>Change from baseline 2 hours post intake</time_frame>
        <population>healthy adult males</population>
        <group_list>
          <group group_id="O1">
            <title>Oleocanthal-rich, D2i2</title>
            <description>Oleocanthal-rich, D2i2 (Extra virgin olive oil containing oleocanthal to oleacein in a 2:1 ratio)&#xD;
D2i2: Oleocanthal provided in a 2:1 ratio compared to oleacein</description>
          </group>
          <group group_id="O2">
            <title>Oleacein-rich, D2i0.5</title>
            <description>Oleacein-rich, D2i0.5 (Extra virgin olive oil containing oleocanthal to oleacein in a 1:2 ratio)&#xD;
D2i0.5: Oleocanthal provided in a 1:2 ratio compared to oleacein</description>
          </group>
          <group group_id="O3">
            <title>Oleocanthal and Oleacein-low, D2i0</title>
            <description>Oleocanthal and Oleacein-low, D2i0 (Extra virgin olive oil containing low amounts of oleocanthal to oleacein, but with a similar total phenolic content as the other two oils)&#xD;
D2i0: No oleocanthal and no oleacein</description>
          </group>
          <group group_id="O4">
            <title>Ibuprofen</title>
            <description>Ibuprofen, 400 mg&#xD;
Ibuprofen: 400 mg of Ibuprofen</description>
          </group>
        </group_list>
        <measure>
          <title>Activated Platelet Oxylipin Production</title>
          <description>Oxylipins derived from cyclooxygenase, lipoxygenase, and cytochrome P450 dependent metabolism of AA were quantified using liquid chromatography with tandem mass spectrometry (LC-MS/MS) in 100 µL of PRP plasma activated with collagen or ADP as well as 100 µL of unactivated PRP plasma collected before and two hours after treatment with EVOO or ibuprofen.&#xD;
Data were mean centered and reported as a % change from baseline.</description>
          <population>healthy adult males</population>
          <units>percentage of change from baseline</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02"/>
                    <measurement group_id="O2" value="-0.45"/>
                    <measurement group_id="O3" value="-0.17"/>
                    <measurement group_id="O4" value="-0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>All participants received all four study interventions. The first three interventions were administered in random order:&#xD;
Oleocanthal-rich, D2i2&#xD;
Oleacein-rich, D2i0.5&#xD;
Oleocanthal and Oleacein-low, D2i0&#xD;
All participants received the last intervention, 400 mg of Ibuprofen, at the fourth (final) study visit.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roberta R Holt</name_or_title>
      <organization>University of California, Davis</organization>
      <phone>530-752-4950</phone>
      <email>rrholt@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

